Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Mutational analysis of the regulatory function of the c-Abl Src homology 3 domain

Abstract

The catalytic activity of the c-Abl tyrosine kinase is tightly regulated by its Src homology 3 (SH3) domain through a complex mechanism that may involve intramolecular binding to Pro242 in the linker region between the SH2 and catalytic domains as well as interactions with a trans-inhibitor. We analysed the effect of mutation or replacement of SH3 on c-Abl tyrosine kinase activity and transformation. Random mutagenesis of SH3 identified several novel point mutations that dysregulated c-Abl kinase activity in vivo, but the RT loop was insensitive to mutational activation. Activating SH3 mutations abolished binding of proline-rich SH3 ligands in vitro, while mutations at Ser140 in the connector between the SH3 and SH2 domains activated Abl kinase activity in vivo and in vitro but did not impair SH3 ligand-binding. Abl was regulated efficiently when its SH3 domain was replaced with a heterologous SH3 from c-Src that binds a different spectrum of proline-rich ligands, but not by substitution of a modular WW domain with similar ligand-binding specificity. These results suggest that the SH3 domain regulates Abl principally by binding to the atypical intramolecular ligand Pro242 rather than a canonical PxxP ligand. Coordination between the SH3 and SH2 domains mediated by the connector region may be required for regulation of Abl even in the absence of SH2 ligand binding.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  • Barila D, Superti-Furga G . 1998 Nat. Genet. 18: 280–282

  • Bedford MT, Chan DC, Leder P . 1997 EMBO J. 16: 2376–2383

  • Brasher BB, Van Etten RA . 2000 J. Biol. Chem. 275: 35631–35637

  • Cartwright CA, Eckhart W, Simon S, Kaplan PL . 1987 Cell 49: 83–91

  • Chan DC, Bedford MT, Leder P . 1996 EMBO J. 15: 1045–1054

  • Dai Z, Pendergast AM . 1995 Genes Dev. 9: 2569–2582

  • Daley GQ, Van Etten RA, Jackson PK, Bernards A, Baltimore D . 1992 Mol. Cell. Biol. 12: 1864–1871

  • Dalgarno DC, Botfield MC, Rickles RJ . 1997 Biopoly. 43: 383–400

  • Dorey K, Barila D, Gavin AC, Nebreda AR, Superti-Furga G . 1999 Biol. Chem. 380: 223–230

  • Erpel T, Superti-Furga G, Courtneidge SA . 1995 EMBO J. 14: 963–975

  • Feng S, Chen JK, Yu H, Simon JA, Schreiber SL . 1994 Science 266: 1241–1247

  • Feng S, Kasahara C, Rickles RJ, Schreiber SL . 1995 Proc. Natl. Acad. Sci. USA 92: 12408–12415

  • Finer MH, Dull TJ, Qin L, Farson D, Roberts M . 1994 Blood 83: 43–50

  • Franz WM, Berger P, Wang JYJ . 1989 EMBO J. 8: 137–147

  • Hirai H, Varmus HE . 1990 Mol. Cell. Biol. 10: 1307–1318

  • Hunter T . 1987 Cell 49: 1–4

  • Jackson P, Baltimore D . 1989 EMBO J. 8: 449–456

  • Kay BK, Williamson MP, Sudol M . 2000 FASEB J. 14: 231–241

  • Kmiecik TE, Shalloway D . 1987 Cell 49: 65–73

  • Lee JC, Hapel AJ, Ihle JN . 1982 J. Immunol. 128: 2393–2398

  • Leung DW, Chen E, Goeddel DV . 1989 Technique 1: 11–15

  • Li S, Ilaria RL, Million RP, Daley GQ, Van Etten RA . 1999 J. Exp. Med. 189: 1399–1412

  • Lim WA, Richards FM . 1994 Nature Struct. Biol. 1: 221–225

  • Liu X, Brodeur SR, Gish G, Songyang Z, Cantley LC, Laudano AP, Pawson T . 1993 Oncogene 8: 1119–1126

  • Mayer BJ, Baltimore D . 1994 Mol. Cell. Biol. 14: 2883–2894

  • Mayer BJ, Jackson PK, Van Etten RA, Baltimore D . 1992 Mol. Cell. Biol. 12: 609–618

  • Palacios R, Steinmetz M . 1985 Cell 41: 727–734

  • Pendergast AM, Muller AJ, Havlik MH, Clark R, McCormick F, Witte ON . 1991 Proc. Natl. Acad. Sci. USA 88: 5927–5931

  • Pisabarro MT, Serrano L . 1996 Biochemistry 35: 10634–10640

  • Piwinica-worms H, Saunders K, Roberts T, Smith A, Cheng S . 1987 Cell 49: 75–82

  • Potts WM, Reynolds AB, Lansing TJ, Parsons JT . 1988 Oncogene Res. 3: 343–355

  • Ren R, Mayer BJ, Cicchetti P, Baltimore D . 1993 Science 259: 1157–1161

  • Seidel-Dugan C, Meyer BE, Thomas SM, Brugge JS . 1992 Mol. Cell. Biol. 12: 1835–1845

  • Shi Y, Alin K, Goff SP . 1995 Genes Dev. 9: 2583–2597

  • Van Etten RA . 1999 Trends Cell Biol. 9: 179–186

  • Van Etten RA, Debnath J, Zhou H, Casasnovas JM . 1995 Oncogene 10: 1977–1988

  • Van Etten RA, Jackson P, Baltimore D . 1989 Cell 58: 669–678

  • Walkenhorst J, Goga A, Witte ON, Superti-Furga G . 1996 Oncogene 12: 1513–1520

  • Welch PJ, Wang JYJ . 1993 Cell 75: 779–790

  • Wen S-T, Van Etten RA . 1997 Genes Dev. 11: 2456–2467

  • Weng Z, Rickles RJ, Feng S, Richard S, Shaw AS, Schreiber SL, Brugge JS . 1995 Mol. Cell. Biol. 15: 5627–5634

  • Xu W, Harrison SC, Eck MJ . 1997 Nature 385: 595–602

  • Young MA, Gonfloni S, Superti-Furga G, Roux B, Kuriyan J . 2001 Cell 105: 115–126

  • Zhu J, Shore SK . 1996 Mol. Cell. Biol. 16: 7054–7062

Download references

Acknowledgements

The authors thank Dr Peter Jackson (Stanford University) for reading the manuscript and Dr Bruce Mayer (University of Connecticut) for reagents and helpful discussions. This work was supported in part by a Howard Hughes Predoctoral Fellowship to B Brasher and by NIH grant CA72465 to RA Van Etten. RA Van Etten is a Scholar of the Leukemia and Lymphoma Society of America and The Carl and Margaret Walter Scholar in Blood Research at Harvard Medical School.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Richard A Van Etten.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brasher, B., Roumiantsev, S. & Van Etten, R. Mutational analysis of the regulatory function of the c-Abl Src homology 3 domain. Oncogene 20, 7744–7752 (2001). https://doi.org/10.1038/sj.onc.1204978

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204978

Keywords

This article is cited by

Search

Quick links